Camostat
As of the edition of 20 October 2026, Camostat is a small molecule: in active development; acts on PRSS1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2024
- Kind
- Small molecule
- Registered trials
- 19, 8 stopped early
- Disease areas
- Infections; Lungs and airways; Blood and lymph; Digestive system; Heart and blood vessels; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PRSS1 | Serine protease 1 | P07477 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 14 | 8 | 1 | 5 |
| Phase 3 | 4 | 1 | 0 | 2 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 19 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Nichi-Iko Pharmaceutical | Lead sponsor of trials | 2020 to now |